Literature DB >> 21813320

High correlation between the Roche COBAS® AmpliPrep/COBAS® TaqMan® HIV-1, v2.0 and the Abbott m2000 RealTime HIV-1 assays for quantification of viral load in HIV-1 B and non-B subtypes.

J C Karasi1, F Dziezuk, L Quennery, S Förster, U Reischl, G Colucci, D Schoener, C Seguin-Devaux, J C Schmit.   

Abstract

BACKGROUND: HIV-1 viral load assays are critical tools to monitor antiretroviral therapy efficacy in HIV-infected patients. Two assays based on real-time PCR are available, the Abbott Real-Time HIV-1 assay (Abbott assay) and the new Roche COBAS(®) AmpliPrep/COBAS(®) TaqMan(®) HIV-1 test, v. 2.0 (TaqMan(®) test v2.0).
OBJECTIVES: We have compared the performance of the two assays in 546 clinical plasma specimens of group M strains from Luxembourg and Rwanda. STUDY
DESIGN: Our analyses focused on subtype inclusivity and platforms accuracy for 328 low level viremia samples.
RESULTS: Strong agreement and linear correlation were observed between the two assays (R(2) = 0.95) over a wide dynamic range. Bland-Altman analysis showed a mean difference of 0.04 log 10 indicating minimal overall viral load quantification differences between both platforms. One subtype C was severely underquantified by TaqMan(®) test v2.0 for which sequence analysis revealed multiple mismatches between the viral sequence and the primer/probe regions. A non significant lower quantification of the Abbott assay was shown for subtype A1 with a mean log 10 difference of 0.24. For specimens under 200 cp/mL, the overall agreement was 90% at the cut-off of 50 cp/mL and 67% at assay's lower limit of detection of 20 and 40 cp/mL. 309 samples were retested by the COBAS(®) AMPLICOR(®) HIV-1 MONITOR Test, v. 1.5 and a lack of agreement between the three assays around their lower limit of quantification was revealed.
CONCLUSIONS: Both real-time tests were closely comparable in the quantification of viral load specimens of ten HIV-1 subtypes and recombinant forms.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21813320     DOI: 10.1016/j.jcv.2011.07.002

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  10 in total

1.  Comparative performances of HIV-1 RNA load assays at low viral load levels: results of an international collaboration.

Authors:  Luke C Swenson; Bryan Cobb; Anna Maria Geretti; P Richard Harrigan; Mario Poljak; Carole Seguin-Devaux; Chris Verhofstede; Marc Wirden; Alessandra Amendola; Jurg Boni; Thomas Bourlet; Jon B Huder; Jean-Claude Karasi; Snjezana Zidovec Lepej; Maja M Lunar; Odette Mukabayire; Rob Schuurman; Janez Tomazic; Kristel Van Laethem; Linos Vandekerckhove; Annemarie M J Wensing
Journal:  J Clin Microbiol       Date:  2013-12-04       Impact factor: 5.948

2.  Ability of two commercially available assays (Abbott RealTime HIV-1 and Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 Version 2.0) to quantify low HIV-1 RNA Levels (<1,000 copies/milliliter): comparison with clinical samples and NIBSC working reagent for nucleic acid testing assays.

Authors:  Alessandra Amendola; Patrizia Marsella; Maria Bloisi; Federica Forbici; Claudio Angeletti; Maria R Capobianchi
Journal:  J Clin Microbiol       Date:  2014-03-26       Impact factor: 5.948

3.  Evaluation of the Aptima HIV-1 Quant Dx Assay Using Plasma and Dried Blood Spots.

Authors:  Malaya K Sahoo; Vici Varghese; Elizabeth White; Meg Winslow; David A Katzenstein; Robert W Shafer; Benjamin A Pinsky
Journal:  J Clin Microbiol       Date:  2016-08-17       Impact factor: 5.948

4.  Cross-platform analysis of HIV-1 RNA data generated by a multicenter assay validation study with wide geographic representation.

Authors:  Cheryl Jennings; Brian Harty; Suzanne Granger; Carrie Wager; John A Crump; Susan A Fiscus; James W Bremer
Journal:  J Clin Microbiol       Date:  2012-06-12       Impact factor: 5.948

5.  The Impact of Low-Level Viraemia on Virological Failure-Results From a Multicenter HIV Antiretroviral Therapy Cohort Study in Yunnan, China.

Authors:  Jing An; Yunfei Lao; Songyuan Tang; Jincheng Lou; Tianshu Li; Xingqi Dong
Journal:  Front Med (Lausanne)       Date:  2022-07-04

6.  Large-scale analysis of the prevalence and geographic distribution of HIV-1 non-B variants in the United States.

Authors:  Michael T Pyne; John Hackett; Vera Holzmayer; David R Hillyard
Journal:  J Clin Microbiol       Date:  2013-06-12       Impact factor: 5.948

7.  Significance and clinical management of persistent low-level viremia and very-low-level viremia in HIV-1-infected patients.

Authors:  Patrick Ryscavage; Sean Kelly; Jonathan Z Li; P Richard Harrigan; Babafemi Taiwo
Journal:  Antimicrob Agents Chemother       Date:  2014-04-14       Impact factor: 5.191

8.  Performance Comparison of Xpert HIV-1 Viral Load Assay and Roche Taqman and Abbott M2000 RT in Bamako, Mali.

Authors:  Bourahima Kone; Drissa Goita; Oumar Dolo; Daouda Traore; Dramane Sogoba; Amadou Somboro; Moumine Sanogo; Anou M Somboro; Nadie Coulibaly; Alou Sanogo; Zoumana Diarra; Madou Traore; Almoustapha I Maiga; Bocar Baya; Yeya Dit Sadio Sarro; Bassirou Diarra; Amadou Kone; Dramane Diallo; Djeneba Dabitao; Jane L Holl; Michael Belson; Sounkalo Dao; Robert L Murphy; Mahamadou Diakite; Souleymane Diallo; Seydou Doumbia; Mamoudou Maiga
Journal:  J AIDS Clin Res       Date:  2020-07-30

Review 9.  Systematic review of the performance of HIV viral load technologies on plasma samples.

Authors:  Kimberly A Sollis; Pieter W Smit; Susan Fiscus; Nathan Ford; Marco Vitoria; Shaffiq Essajee; David Barnett; Ben Cheng; Suzanne M Crowe; Thomas Denny; Alan Landay; Wendy Stevens; Vincent Habiyambere; Jos Perrins; Rosanna W Peeling
Journal:  PLoS One       Date:  2014-02-18       Impact factor: 3.240

10.  Use of reverse-transcriptase-based HIV-1 viral load assessment to confirm low viral loads in newly diagnosed patients in Switzerland.

Authors:  Beatrice N Vetter; Cyril Shah; Jon B Huder; Jürg Böni; Jörg Schüpbach
Journal:  BMC Infect Dis       Date:  2014-02-13       Impact factor: 3.090

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.